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ANTICYTOKINE TREATMENT OF ESTABLISHED 
TYPE II COLLAGEN-INDUCED ARTHRITIS IN DBA/1 MICE
A Comparative Study using Anti-TNFa, Anti-IL-lo//3, and IL-IRa
LEO A. B. JOOSTEN, MONIQUE M. A. HELSEN, FONS A. J. v a n  d e  LOO, and
WIM B. v a n  d e n  BERG
Objective. To examine the role of tumor necrosis 
factor a  (TNFa), interleukin-la (IL-la), and UL-lfi in 
collagen-induced arthritis (CIA), immediately after on­
set and during the phase of established arthritis.
Methods. Male DBA/1 mice with collagen- 
induced arthritis were treated with antibodies against 
murine TNF a  and IL-la//? at different time points of 
the disease. IL-1 receptor antagonist (IL-IRa) was ad­
ministered using Alzet osmotic minipumps. The effect of 
anticytokine treatment was monitored by visual scoring. 
Histology and cytokine reverse transcription polymerase 
chain reaction (RT-PCR) analyses were performed at 
the end of the treatment period.
Results. Anti-TNFa  treatment showed efficacy 
shortly after onset of the disease, but had little effect on 
fully established CIA. Histologic analysis after early 
treatment revealed that anti-TNFa significantly re­
duced joint pathology, as determined by infiltration of 
inflammatory cells and cartilage damage. Anti-IL-la//? 
treatment ameliorated both early and full-blown CIA. 
This clear suppression of established arthritis was con­
firmed by administration of high doses of IL-IRa. 
Dose-response experiments showed that a continuous 
supply of 1 mg/day was needed for optimal suppression. 
Histologic analysis showed markedly reduced cartilage 
destruction both in the knee and the ankle joints. 
Autoradiography demonstrated full recovery of chon­
drocyte synthetic function of articular cartilage. In
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addition, we found that the IL-1/3 isoform plays a 
dominant role in established CIA. Profound suppression 
of CIA was observed with anti-IL-1/3, although elimi­
nation of both IL -la  and IL-1/3 still gave better protec­
tion. Analysis of messenger RNA with RT-PCR revealed 
that IL-1/3 was highly upregulated in synovium and 
cartilage at late stages of CIA, whereas anti-IL-1/3 
treatment markedly reduced IL-1/3 message in the 
synovium.
Conclusion. The present study identified different 
TNFa/IL-1 dependencies in various stages of CIA and 
revealed that blocking of TNF a: does not necessarily 
eliminate IL-1. Continuous, high doses of IL-IRa are 
needed to block CIA.
Rheumatoid arthritis (RA) is characterized by 
chronic inflammation in joints and concomitant de­
struction of cartilage and bone. Although the disease is 
generally considered an autoimmune process, the auto­
antigen is still unknown, thus hampering specific 
immunomodulation as a straightforward therapeutic 
approach. In fact, detailed analyses of mediator pro­
duction in inflamed synovial tissue have revealed a 
relative lack of T cell factors and an abundance of 
cytokines and growth factors, which are produced by 
macrophages and synovial fibroblasts (1,2). Fortu­
nately, considerable hierarchy seems to exist in this 
plethora of factors, and tumor necrosis factor a 
(TNFa) and interleukin-1 (IL-1) seem of pivotal im­
portance in arthritis (3-5). It has been claimed that 
TNFa is driving most of the IL-1 production in the 
inflamed synovia of RA patients (6), making it a prime 
target for therapy. This has been further substantiated 
by the demonstration of arthritis in TNFa-transgenic 
mice and of the efficacy of anti-TNFa treatment in 
collagen-induced arthritis (CIA) in the mouse (7-9).
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The first clinical trials with neutralizing antibodies 
against TNFa have demonstrated efficacy in humans
with RA (10-12).
CIA is a widely used experimental model of 
polyarthritis. It can be induced in susceptible strains of 
mice and rats by immunization with type II collagen, 
the major component of articular cartilage, and has 
histopathologic features in common with RA (13-16). 
Earlier studies revealed that the expression of this 
autoimmune arthritis can be enhanced with passive 
addition of cytokines like TNFa, IL-1, and transform­
ing growth factor ¡3 (TGF/3), whereas TGF/3 and 
antibodies to TNFa prevented the onset of disease 
(17-21). Subsequent studies using antibodies and sol­
uble TNFa receptor fusion protein analyzed the effect 
of TNFa neutralization after the onset of CIA. Signif­
icant amelioration was found both macroscopically 
and histologically (8,9,22). However, recent studies, 
using neutralizing antibodies to IL-1 in CIA, suggest 
that elimination of this cytokine was at least as effec­
tive (23,24). Moreover, studies in other arthritis mod­
els have provided evidence that IL-1 is perhaps not 
always the dominant cytokine in the inflammatory 
process, but is certainly of pivotal importance in 
cartilage destruction (25,26).
In the present study, we compared the relative 
efficacy of anti-TNFa and anti-IL-1 a!fi treatment in 
murine CIA, using concomitant treatment protocols in 
large groups of arthritic mice. Moreover, treatment 
was started at different time points after the onset of 
arthritis and in addition to macroscopic scores for 
arthritis, we investigated the histopathology in sec­
tions of knees and ankle joints. It was found that 
anti-TNFa was effective at the onset of arthritis but 
less so at later stages, whereas anti-IL-1 at(3 was also 
highly effective in established disease, with a major 
emphasis on reduction of cartilage destruction. We 
confirmed the importance of IL-1, using IL-1 receptor 
antagonist (IL-IRa) treatment. A critical observa­
tion in the latter experiments was the need of contin­
uous, high concentrations of IL-IRa, supplied by 
osmotic minipumps. Finally, we examined the relative 
role of IL-1/3 and IL-1 a and analyzed message expres­
sion in synovium and cartilage for TNFa, IL-1/3, and 
IL-IRa. It is clear from observations in this animal 
model that IL- l i s a  pivotal mediator in both early and 
late disease, whereas blocking of TNFa does not 
necessarily eliminate IL-1. Given the cartilage- 
destroying character of IL-1, this argues at least for a
consideration of both TNFa and IL-1 as therapeutic 
targets in RA.
MATERIALS AND METHODS
Animals. Male DBA/1 Lac/J mice were obtained 
from Jackson Laboratories (Bar Harbor, ME). Male C57B1/6 
mice, used for induction of streptococcal cell wall (SCW) 
arthritis, were bred in our own facilities. Mice were housed 
in filter top cages, and water and food were provided ad 
libitum. DBA/1 mice were immunized at the age of 9-10 
weeks and C57B1/6 mice were used at the age of 10-12 
weeks.
Materials. LPS (Escherichia coli 0111:84), ethidium 
bromide, hamster Ig, rat Ig, rabbit Ig, and bovine serum 
albumin (BSA) were purchased from Sigma (St. Louis, MO). 
Taq DNA polymerase, 100-bp DNA marker, TRIzol reagent, 
and agarose were obtained from Life Technologies (Breda, 
The Netherlands). GAPDH, ^-microglobulin (/^-m), IL-1/3, 
IL-IRa, TNFa, and tissue inhibitor of metalloproteinases 
(TIMP) primers were purchased from Pharmacia Biotech 
(Roosendaal, The Netherlands). Internal DNA construct 
(Pmus) was a kind gift of Dr. D. Shire (Sanofi Recherche, 
Labfcge, France) (27). Freund’s complete adjuvant (FCA) 
and Mycobacterium tuberculosis (MT; strain H37Ra) were 
obtained from Difco (Detroit, MI). Osmotic minipumps 
(model 1007D) were purchased from Alza (Palo Alto, CA).
Cells producing rat anti-murine TNFa IgGl (VIq) 
were a kind gift of P. H. Krammer (German Cancer Re­
search Centre, Heidelberg, Germany) (28). Rabbit anti­
murine IL-1 a//3 polyclonal antibodies were prepared in our 
own laboratory by one of us (AAJVDL) (25,26). Polyclonal 
rabbit anti-murine IL-1 a and monoclonal hamster anti-murine 
IL-1 ¡3 were generously provided by Robert Schreiber (Wash­
ington University Medical School, St Louis, MO), in conjunc­
tion with Merck Research Laboratories (Rahway, NJ). Human 
recombinant IL-IRa was kindly provided by Synergen «'Boul­
der, CO).
Collagen preparation. Articular cartilage was ob­
tained from the knee joints of 1-2-year-old cows. Bovine 
type II collagen was prepared according to the method of 
Miller and Rhodes (29). Collagen was dissolved in 0.05M 
acetic acid (10 mg/ml) and stored at -70°C.
Induction of CIA. Bovine type II collagen was diluted 
with 0.05M acetic acid to a concentration of 2 mg/ml and was 
emulsified in an equal volume of FCA (2 mg/ml of MT 
H37Ra). The mice were immunized intradermally at the base 
of the tail with 100 /xl of emulsion (100 n% of collagen). On 
day 21, the animals were given booster injections intraperi- 
toneally with 100 /ug of type II collagen dissolved in phos­
phate buffered saline (PBS). This resulted in the onset of 
arthritis around day 28 in 20-40% of the mice. Mice with 
arthritis were selected at this time point to be used in studies 
of “classic” CIA.
Acceleration of CIA. Mice without any macroscopic 
signs of arthritis on day 28 were used for LPS-accelerated 
CIA. Arthritis onset was initiated by a single intraperitoneal 
injection of 40 ng of LPS (30). This resulted in the onset of 
CIA within 3 days, and on day 35, full-blown arthritis was
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noted in the paws of more than 95% of the animals. Thus, 
anticytokine treatments were performed in 2 CIA models: 
classic and accelerated. The histopathologic changes in the 
knee and ankle joints were comparable in accelerated CIA 
and classic CIA. As described previously, administration of 
40 n% of LPS to nonimmunized DBA/1 mice did not result in 
any macroscopic or histologic abnormalities (31).
Assessment of CIA. Mice were examined visually for 
the appearance of arthritis in the peripheral joints, and 
scores for arthritis severity were given (macroscopic score) 
as previously described (24,31). Mice were considered to 
have arthritis when significant changes in redness and/or 
swelling were noted in the digits or in other parts of at least 
2 paws. At later time points, ankylosis was also included in 
the macroscopic scoring.
The clinical severity of arthritis was graded on a 
scale of 0-2 for each paw, according to changes in redness 
and swelling (0 = no change, 0.5 = significant, 1.0 = 
moderate, 1.5 = marked, and 2.0 = maximal swelling and 
redness and later, ankylosis). The macroscopic score was 
the cumulative value for all paws (mean ± SD), with a 
maximum of 8. The macroscopic score was assessed by 2 
independent, blinded observers (LABJ, MM AH).
Neutralizing anticytokine antibodies/IL-lRa. Hybrid- 
oma cells (3 x 106) producing rat anti-murine TNFa (Vlq) 
were injected into nude Balb/c mice, and after 3 weeks, 
ascites fluid was collected. Thereafter Ig were isolated using 
a protein G column. This antibody (IgGl) showed efficacy in 
LPS-mediated lethal shock models (28) and in the L929 
bioassay. The neutralizing capacity of this antibody was 3.5 
ng of TNFa per /¿g in the latter assay. Polyclonal rabbit 
antibodies were raised against murine recombinant IL-la 
and IL-1/3 (25,26). The isotype-specific antibodies showed 
no cross-reactivity with a number of other cytokines, such as 
IL-6, TNFa, or granulocyte-macrophage colony-stimulating 
factor. The antibodies have been demonstrated to show 
neutralizing capacity both in vitro and in vivo. One micro­
gram of purified Ig neutralized 50-100 pg of IL-1 in the 
NOB-1 bioassay. To confirm the anti-IL-1 a//3 treatment 
results, we compared the in vivo efficacy of our anti-IL-1 
antibodies with anti-IL-1 antibodies from other sources. To 
this end, we used rabbit anti-IL-1 a and monoclonal hamster 
anti-IL- 1(S (from Robert Schreiber), which neutralized 35 pg 
of IL-la per n% of antibody and 175 pg of IL-1/3 per jug of 
antibody, respectively.
IL-IRa was administered using osmotic minipumps. 
Pumps were implanted into the peritoneal cavity on day 34 
after immunization (6 days after acceleration by LPS), giving 
sustained release of IL-IRa for the next 7 days. All anti­
cytokine agents used contained no LPS, as measured by the 
Limulus amebocyte assay.
Anticytokine treatment of CIA. To investigate the 
effect of anti-IL-la//3 or anti-TNFa treatment at different 
phases of classic CIA, a single dose of these antibodies was 
injected intraperitoneally at different time points after the 
onset of CIA. We injected 0.6 mg of rabbit anti-IL-la or 
anti-IL-1/3 polyclonal antibodies or 75 /ig of rat monoclonal 
anti-TNFa. Dose-response experiments in established CIA 
were performed with 0.6 mg of polyclonal rabbit anti-IL-la
and 0.12 mg of monoclonal hamster anti-IL-1/3 (from Robert 
Schreiber) as the highest doses, which had the same neutral­
izing capacity as 0.6 mg of rabbit anti-IL-1 a and anti-IL-1/3 
as prepared by one of us (AAJVDL). Daily administration of 
anti-TNFa were performed during accelerated CIA, with a 
15-fxg dose of rat anti-TNFa for a period of 7 days. As 
controls in the anti-IL-1/TNFa studies, we injected the same 
amounts of normal rabbit, rat, or hamster Ig.
IL-IRa treatment was started on day 34 after immu­
nization by implantation of osmotic minipumps, which re­
leased 0.12-1.2 mg of IL-IRa per day. As a control, we 
implanted osmotic pumps, which released 1.2 mg of BSA per 
day. Arthritis was assessed every 2 days, starting on day 28 
after immunization with collagen. Knee and ankle joints 
were isolated and processed for light microscopy 7 days after 
the start of anticytokine treatment, unless stated otherwise. 
Tissue samples for measurements of messenger RNA 
(mRNA) were also isolated at this time point.
Induction of endotoxic shock. Mice, C57BJ/6 were 
iryected intravenously into the tail vein with LPS (100 ¡xg) in 
a 200-/ul saline solution and monitored for survival for 7 
days. All deaths occurred within 3 days of LPS administra­
tion. Rat anti-murine TNFa (75 jug) was injected intraperi­
toneally 4 hours before the induction of endotoxic shock.
SCW preparation and induction of SCW arthritis. 
Streptococcus pyogenes T12 organisms were cultured over­
night in Todd-Hewitt broth. Cell walls were prepared as 
described previously (32). The resulting 10,000# supernatant 
was used throughout the experiments. These preparations 
contained 11% muramic acid. Bacteria were kindly provided 
by Dr. M. Hazenberg (Erasmus University, Rotterdam, The 
Netherlands). Unilateral arthritis was induced by intraartic- 
ular injection of 25 /ug of SCW (dry weight) in 5 /ul of PBS 
into the right knee joint of naive mice. As a control, PBS was 
injected into the left knee joint.
Measurement of SCW-induced arthritis. SCW arthri­
tis was quantified by the ""Tc-uptake method (33). This 
method measures by external gamma counting the accumu­
lation of a small radioisotope at the site of inflammation due 
to local increased blood flow and tissue swelling. The 
severity of inflammation is expressed as the ratio of the 
" mTc uptake in the right (inflamed) knee joint over that in 
the left (control) knee joint. All values exceeding 1.10 were 
considered inflammation.
Anti-TNFa treatment of SCW-induced arthritis. To 
examine the role of TNFa during the onset of SCW-induced 
arthritis, a single injection of 75 /ug of rat anti-TNFa anti­
bodies was given, 1 hour before induction of SCW, As a 
control, we used 75 fjg of rat Ig. Knee joint swelling was 
measured on days 1, 2, and 4 of the arthritis.
RNA isolation. Mice were killed by cervical disloca­
tion, immediately followed by dissection of the patella with 
adjacent synovium (34). Two synovium biopsies (3-mm 
diameter) were taken with a disposable biopsy punch 
(Stiefel, Wachtersbach, Germany) from this specimen, one 
from the lateral and one from the medial side. The synovium 
samples were immediately frozen in liquid nitrogen. Patellae 
were transferred to a 5% EDTA solution and kept on ice for 
4 hours. Thereafter, the cartilage layer was stripped as
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previously described (35). This procedure does not affect 
mRNA expression.
The total RNA of a pool of 10 cartilage samples was 
extracted with 1 ml of TRIzol reagent, an improved single- 
step RNA isolation method based on the method de­
scribed by Chomczynski and Sacchi (36). Five separate 
synovium samples were ground into powder using a micro- 
dismembrator II (B. Braun, Melsungen, Germany). Total 
RNA was extracted in 1 ml TRIzol reagent in a procedure 
similar to that used for cartilage samples.
Polymerase chain reaction (PCR) amplification. One 
microgram of synovial RNA and the total amount of cartilage 
RNA was used for reverse transcription PCR (RT-PCR). 
Messenger RNA was reverse-transcribed to complementary 
DNA (cDNA) using oligo-dT primers and one-twentieth of 
the cDNA was used in 1 PCR amplification. PCR was per­
formed according to a standard protocol. Message for 
GAPDH, IL-1/3, Il-IRa, and TNFa was amplified using the 
primers described elsewhere (37—40). Primers for TIMP were 
designed using Oligo 4.0 (National Bioscientist, Plymouth, 
MN) or Primer (Whitehead Institute, Cambridge, MA). The 
results are presented as the relative increase in mRNA 
expression compared with noninflamed control samples 
from normal DBA/1 mice. The relative increase in mRNA 
was calculated as follows: 1.9 (amplification factor [41]) to 
the power of n, where n is the difference in the number of 
cycles showing identical staining intensity for experimental 
and noninflamed control tissue. IL-1/3, TNFa, IL-IRa, and 
TIMP mRNA levels were corrected for GAPDH message, if 
needed.
To validate the calculated values for the mRNA 
levels, we also performed competitive PCR for j^m and 
IL-1/3 (27). A serial dilution of an internal DNA standard 
(Pmus) was added to a fixed amount of cDNA (one-twentieth 
of the cDNA). The IL-1/3 mRNA levels were corrected for 
the amount of /32m.
Histology. Mice were killed by ether anesthesia; 
ankle and knee joints were removed and fixed for 4 days in 
4% formalin. After décalcification in 5% formic acid, the 
specimens were processed for paraffin embedding. Tissue 
sections (7 /um) were stained with hematoxylin and eosin or 
Safranin O. Histopathologic changes were scored according 
to the following parameters. Infiltration of cells was scored 
on a scale of 0-3, depending on the amount of inflammatory 
cells in the synovial cavity and synovial tissues. Proteogly­
can depletion was determined using Safranin O staining. The 
loss of proteoglycans was scored on a scale of 0-3, ranging 
from fully stained cartilage to destained cartilage or com­
plete loss of articular cartilage. A characteristic parameter in 
CIA is the progressive loss of articular cartilage. This 
destruction was separately graded on a scale of 0-3, ranging 
from the appearance of dead chondrocytes (empty lacunae) 
to a complete loss of articular cartilage. Histopathologic 
changes in the knee joints were scored in the patellofemoral 
region on 5 semi-serial sections of the joint. For the ankle 
joint, we scored the calcaneous region. Scoring was done in 
a blinded manner by 2 observers (LABJ, MMAH), as 
described earlier (24).
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Figure 1. Time-course of tumor necrosis factor a/interleukin-1 
(TNFa/IL-1) involvement in classic collagen-induced arthritis 
(CIA). A single treatment with anti-TNFa or anti-IL-1 a//3 was given 
(A and B). At time points indicated by arrows, separate groups were 
injected with either control Ig or anticytokine. CIA was scored 
visually by 2 independent observers (0-8 cumulative value for all 
paws; see Materials and Methods). This experiment was repeated 
twice, with similar outcomes. A, rat anti-TNFa, 75 ug; •
control rat Ig, 75 fig. B, ▲ = rabbit anti-IL-1 a/(3, 0.6 mg each; •  = 
control rabbit Ig, 1.2 mg. Values are the mean ± SD of at least 10 
mice per group (n = 3 experiments), i.p. = intraperitoneal.
Statistical analysis. Differences between experimen­
tal groups were tested using the Wilcoxon rank test, unless 
stated otherwise.
RESULTS
Time course of TNFa/IL-1 involvement in classic 
CIA. At various time points after the onset of classic 
CIA, mice were given a single intraperitoneal injection
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of antibodies raised against murine TNFa or murine 
IL -la  and IL-1/3. When 75 /¿g of monoclonal 
anti-TNFa was given just after onset (day 30), a 
marked reduction of arthritis was noted. The effect 
was less pronounced when treatment was started on 
day 2 after onset (day 32), whereas no significant relief 
was seen when treatment was delayed till day 7 after 
onset (Figure 1A). In contrast, after neutralization of 
IL-1 with a combination of antibodies against both 
isoforms, IL -la  and IL-1/3, complete prevention of 
CIA onset was noted upon early treatment. Of inter­
est, a pronounced suppression was still observed when 
treatment was given on day 2 after onset.
Unlike the effect of anti-TNFa, anti-IL-1 aJ¡3 
treatment was also able to significantly suppress es­
tablished CIA. Figure IB shows a macroscopic arthri­
tis score of 5 on day 35, which slowly increased to 5.5 
in the control group on day 42, whereas the score was
MACROSCOPIC SCORE
Table 1. Histology after anticytokine treatment classic of collagen- 
induced arthritis*
Proteo­
Start of Cartilage glycan Day of
Group treatment Infiltrate damage depletion killing
Knee joints
Ratlg Day 30 1.5 4- 0.6 1.0 + 0.6 1.9 ± 0.8 37
Rabbit Ig Day 30 1.4 0.7 0.9 ± 0.5 1.8 ± 0.9 37
TNFoAb Day 30 0.9 0.3 0.6 ± 0.5 1.1 ± 0.5 37
Anti-IL-1 Day 30 0.1 -f* O.lt 0.1 it O.lt 0.1 ± O.lt 37
Ratlg Day 32 1.4 0.4 1.1 0.3 2.4 ± 0.6 39
Rabbit Ig Day 32 1.5 ± 0.5 1.0 it 0.4 2.5 ± 0.3 39
TNFoAb Day 32 1.0 ± 0.5 0.7 it 0.5 1.8 ± 0.6 39
Anti-IL-1 Day 32 0.1 O.lt 0.1 ± O.lt 0.1 ± O.lt 39
Rat Ig Day 35 1.3 it 0.4 1.2 0.3 2.2 ± 0.5 42
Rabbit Ig Day 35 1.4 0.3 1.3 it 0.4 2.1 ± 0.4 42
TNFoAb Day 35 1.2 0.5 1.0 0.5 2.0 ± 0.6 42
Anti-IL-1 Day 35 0.6 ± O.lt 0.5 ÌI 0.3t 0.9 ± 0.2t 42
Ankle joints
Rat Ig Day 30 1.5 0.3 0.9 KNi m I 0.4 1.6 ± 0.4 37
Rabbit Ig Day 30 1.6 Hh 0.4 0.8 it 0.4 1.7 ± 0.5 37
TNFoAb Day 30 0.9 0.5 0.6 ■jmi 0.5 I i +i « 1 ■ 0.7 37
Anti-IL-1 Day 30 0.1 O.lt 0.1 ± O.lt 0.2 ± 0.2t 37
Ratlg Day 32 2.0 0.5 1.0 * * * * * 0.3 2.4 ± 0.3 39
Rabbit Ig Day 32 1.9 0.4 0.9 0.2 2.3 ± 0.4 39
TNFoAb Day 32 1.3 0.5 0.7 it 0.3 1.6 ± 0.8 39
Anti-IL-1 Day 32 0.2 Hh O.lt 0.1 ± O.lt 0.2 ± 0.2t 39
Ratlg Day 35 1.9 0.4 1.1 0.2 2.0 ± 0.5 42
Rabbit Ig Day 35 1.8 0.2 1.0 H- 0.3 1.9 ± 0.3 42
TNFoAb Day 35 1.7 0.4 1.0 m | « 0.3 1.9 ± 0.5 42
Anti-IL-1 Day 35 0.8 Hh 0.21- 0.5 it 0.2t 1.0 ± 0.2t 42
* Start of treatment represents the number of days after immuniza­
tion of DBA/1 mice with bovine type II collagen. Synovial infil­
trates, cartilage damage, and proteoglycan depletion were scored on 
a scale of 0-3. Values are the mean ± SD. TNFa = tumor necrosis 
factor o; IL-1 = interleukin-1. 
t P <  0.01 versus controls, by Wilcoxon rank test.
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Figure 2. Treatment of accelerated CIA with different doses 
anti-TNFa/anti-IL-1. A, A single injection of rat anti-TNFa was 
given just after disease onset (day 31; arrow), at the doses shown. 
As a control, 75 /jg of rat Ig was injected. B, An injection of rabbit 
anti-IL-la/monoclonal hamster IL-l/3 (at the first 3 doses shown) 
was given on day 32 (arrow), when arthritis was fully developed. As 
a control, 0.6 mg of rabbit Ig and 0.12 mg of hamster Ig were injected 
at the same time point. Similar results with rabbit anti-IL-1 alfi 
antibodies (0.6/0.6 mg ♦ ) were found in accelerated CIA as in classic 
CIA (see Figure IB). * = P < 0.01 versus controls, by Wilcoxon 
rank test. Values are the mean ± SD for at least 10 mice per group. 
See Figure 1 for definitions.
reduced below 2 by treatment on day 35 with anti-IL- 
1 a//3. When anti-IL-1 al(3 treatment was delayed till 
day 56, a phase characterized by joint ankylosis, no 
significant suppression of macroscopic signs was 
noted (data not shown).
In addition to macroscopic scoring, we ana-
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Table 2. Histology after anticytokine treatment of accelerated collagen-induced arthritis*
Group
Start of 
treatment Infiltrate
Cartilage
damage
Proteoglycan
depletion
Knee joints
Rat Ig Day 31 1.4 ±  0.6 1.2 ±  0.6 2.0 ± 0.9
Anti-TNFa, 225 ¿tg Day 31 0.8 ±  0.7 1.0 ± 0.7 1.7 ± 0.6
Rabbit Ig Day 32 1.4 ±  0.3 1.1 ±  0.6 2.1 ± 0.4
Anti-IL-1 o//3
0.06/0.012 mg Day 32 0.6 ±  0.5 0.8 ±  0.8 1.3 ± 0.7
0.2/0.04 mg Day 32 0.4 ±  0.2t 0.5 ± 0.5t 0.6 ± 0.5t
0.6/0.12 mg Day 32 0.2 ± 0.2t 0.4 ±  0. If 0.4 ± 0.5t
Control Day 34 1.5 ± 0.7 1.7 ± 0.8 2.2 ± 0.8
IL-lRa, 1.2 mg/day Day 34 0.4 ± 0.2t 0.6 ± 0.2t 0.6 ± 0.4t
Ankle joints
Ratlg Day 31 1.7 ± 0.5 0.9 ±  0.3 1.8 ± 0.6
Anti-TNFa, 225 fig Day 31 1.0 ± 0.7 0.6 ± 0.5 1.2 ± 0.6
Rabbit Ig Day 32 1.9 ± 0.5 0.9 ±  0.2 2.2 ± 0.4
Anti-IL-1 alp
0.06/0.012 mg Day 32 1.0 ± 0.3t 0.5 ± 0.2t 0.8 ± 0.2t
0.2/0.04 mg Day 32 0.8 ± 0.4t 0.4 ± 0.4t 0.7 ± 0.5t
0.6./0.12 mg Day 32 0.4 ± 0.2t 0.3 ±  0.2t 0.5 ± 0.5t
Control Day 34 1.9 ±  0.4 1.4 ±  0.3 2.0 ± 0.8
IL-lRa, 1.2 mg/day Day 34 0.7 ± O.lt 0.5 ±  0.2t 0.5 ± 0.2t
* For details, see Table 1. Histology was performed 7 days after the start of anticytokine treatment. 
Control was 1.2 mg of bovine serum albumin. Values are the mean ±  SD. TNFa = tumor necrosis 
factor a;  IL-1 alfi =  interleukin-1 a !¡3; IL-lRa =  IL-1 receptor antagonist, 
t  P  <  0.01 versus controls, by Wilcoxon rank test.
lyzed the histologic changes in both knee and ankle 
joints on day 7 after anticytokine treatment. Anti- 
TNF a  treatment had only a slight effect on this para­
meter. Cellular infiltration was marginally reduced 
when treatment was given early. No effect was seen 
after late treatment (Table 1). In contrast, anti-IL-1 al(3 
treatment highly reduced cellular infiltration, even 
when treatment was given on day 35. Of importance, 
cartilage proteoglycan depletion and damage to the 
articular surface were also highly reduced by anti-IL-1 
(Table 1). This set of data indicates that TNFa is 
involved in CIA onset, but plays a minor role at later 
stages, whereas IL-1 is a dominant mediator in both 
the onset and perpetuation of CIA.
Anti-IL-1 and anti-TNF a  treatment of acceler­
ated CIA. Experiments were also performed in mice 
with LPS-accelerated CIA. Selected mice, showing no 
clear signs of CIA on day 28, received a single intra- 
peritoneal injection of 40 /xg LPS. Anticytokine treat­
ment was given on day 31, when the animals showed
definite arthritis. When accelerated CIA was treated
i
on day 31 with a single dose of 75 /ug of anti-TNF a, 
some suppression of the arthritis was noted. A low
dose of 7.5 ¡ug was without effect. A higher dose (225 
fig) did not show greater efficacy compared with 75 ¡jg 
(Figure 2A).
As found in the classic CIA, treatment of accel­
erated CIA with anti-IL- la//3 resulted in a complete 
suppression of the arthritis (Figure 2B). To confirm 
these findings, similar studies were done with yet- 
another source of anti-IL-1 antibodies. Rabbit anti- 
IL -la  combined with monoclonal hamster anti-IL-1/8 
showed a dose-dependent suppression of CIA (Table 2). 
These findings were confirmed histologically (Figure 3).
Efficacy of anti-TNFa treatment. The studies 
described above were performed with monoclonal rat 
anti-TNFa antibodies (Vlq). To exclude the possibil­
ity that the apparent inefficacy of anti-TNFa treatment 
was related to inferior pharmacokinetics or inadequate 
neutralization, a number of control experiments were 
performed. First, we tested the efficacy of rat mono­
clonal anti-murine TNFa (Vlq) in LPS-induced shock. 
A single intraperitoneal injection of 75 ¡jug completely 
prevented lethality when 100 /ug of LPS was inj ected 
intravenously 4 hours later. Second, we performed 
daily dosing for 7 days during CIA. As can be seen in
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Figure 3. Hematoxylin and eosin-stained frontal sections of knee joints on day 42 of CIA. A, Arthritic knee joint of a mouse treated with 
control IgG on day 30. B, Knee joint of a mouse treated with rat anti-TNFa (225 fxg) on day 30. C, Knee joint of a mouse treated with rabbit 
anti-IL-la//3 (0.6 mg of each antibody) on day 30. D, Autoradiograph showing 35S-sulfate incorporation in an arthritic joint on day 42. E, 
Autoradiograph of a similar region after treatment with IL-1 receptor antagonist (1.2 mg/day for 7 days, starting on day 34). Note the restoration 
of chondrocyte synthetic function, visualized by distinct labelling. P = patella; F = femur; JS = joint space; C = cartilage; S = synovium. See 
Figure 1 for other definitions. Original magnification x 200.
Figure 4A, this did not result in more marked suppres­
sion of the macroscopic score as compared with the 
findings in Figure 2A. Finally, we treated SCW- 
induced arthritis with a single injection of 75 /ug of 
anti-TNFa. As can be seen in Figure 4B, clear sup­
pression of knee joint swelling was found on days 1,2, 
and 4 in this bacterial arthritis model.
Confirmation with IL-lRa. To further substan­
tiate the important role of IL-1, arthritic mice were
continuously infused with IL-lRa from day 34, using 
osmotic minipumps. This experiment was repeated 3 
times at the high dosage (1.2 mg of IL-lRa per day), 
showing a marked and consistent decline of the arthri­
tis within a few days after the start of treatment. 
Moreover, there was always a slight suppressive effect 
when control minipumps were implanted, probably 
related to the effects of stress. In control arthritic mice 
without minipumps, the arthritis score increased
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Figure 4. Anti-TNF a treatment of CIA and streptococcal cell wall 
(SCW)-induced arthritis. A, Daily doses of 75 ¡xg were given for 7 
days in mice with accelerated CIA; arthritis was scored macroscop- 
ically in the paws. B, Unilateral SCW-induced arthritis was treated 
with a single dose of anti-TNF a (75 /jg), given intraperitoneally 
(I.P.) 1 hour before arthritis induction. Knee joint swelling was 
determined by the " mTc-uptake method. A right/left (R/L) ratio of 
1.1 or more indicates knee joint inflammation. * = P < 0.01 versus 
control (rat Ig at 75 /ug), by Wilcoxon rank test. Values are the mean
± SD of at least 10 mice per group, C = 
anti-TNFa. See Figure 1 for other definitions.
control; a-TNF
slightly or remained constant from day 34, whereas in 
mice with control minipumps, some suppression was 
consistently seen. Figure 5 A shows a typical example 
of a dose-response experiment. It is clear that rela­
tively high doses of IL-IRa are needed to obtain 
pronounced suppression. An intermediate dose of 0.4 
mg/day still showed significant suppression, but 0.12 
mg/day was ineffective. Similar observations were 
noted in mice with classic CIA (Figure 5B). Histology 
performed in the highest dose group confirmed the 
pronounced suppression of cellular infiltration and
cartilage damage (Table 2), as noted with neutralizing 
anti-IL-1 antibodies.
In addition to histology, we performed auto­
radiography to get an impression of the metabolic 
activity of the articular chondrocytes. Pronounced 
suppression of 35S-sulfate incorporation, reflecting
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Figure 5. Interleukin-1 receptor antagonist (IL-lra) treatment of 
accelerated and classic CIA. A, On day 6 after acceleration of CIA, 
mice were selected based on visual score, and grouped into 4 groups 
with equal scores for arthritis. Osmotic minipumps (100 /ui) were 
loaded with 100 (1.2 mg/day), 30 (0.4 mg/day), or 10 (0.12 mg/day) 
mg/ml of recombinant human IL-lra and implanted intraperito­
neally. Bovine serum albumin (100 mg) was used as a control. Mice 
were scored daily for arthritis severity, by 2 independent observers.
B, IL-lra treatment (1.2 mg/day) of classic CIA was started on day 
34 after immunization by intraperitoneal implantation of osmotic 
pumps. Values are the mean ± SD of 10 mice per group. * = P <
0.01 versus controls, by Wilcoxon rank test. See Figure 1 for other 
definitions.
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Figure 6. Relative role of IL-la and IL-1/3 in CIA. Into separate 
groups of mice with established CIA (day 32), we injected anti- 
IL-1 a (anti-IL-la; 0.6 mg), anti-IL-1 /3 (anti-IL-1 b; 0.6 mg), or the 
combination of both (anti-IL-lab; 1.2 mg). Values are the mean ±  
SD of at least 10 mice per group. * = P < 0.01 versus controls, by 
Wilcoxon rank test. See Figure 1 for other definitions.
inhibited proteoglycan synthesis, was noted in the 
control arthritic mice on day 42. In contrast, the 
IL-1 Ra-treated animals showed marked 35S-sulfate 
incorporation, which was not significantly different 
from the metabolic activity found in nonarthritic 
DBA/1 mice (Figure 3). This indicates that IL-1 is a 
pivotal mediator in this suppression.
Relative roles of IL-laand IL-1/3. To investigate 
the relative contributions of IL-1 a  and IL-1/3, we 
injected mice with either rabbit polyclonal anti-IL-la 
or anti-IL-1/3, on day 32. Selective neutralization of 
IL-1/3 was sufficient to cause marked suppression of 
arthritis (Figure 6). In a repeat experiment (not shown) 
we used hamster monoclonal anti-IL-1/3 antibodies, 
which showed roughly similar efficacy. In contrast to 
the pronounced effect of anti-IL-1/3, we did not observe 
a major suppression with selective anti-IL-1 a treatment. 
However, it is clear that the most optimal suppression 
was reached with the combination (Figure 6).
Cytokine mRNA levels in the arthritic joint. In a 
repeat experiment, groups of mice were treated with
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CIA with anti-IL-1 /3 (Anti-IL-lb) was started at 2 different time points, day 32 (d32) and day 35 (d35) (arrows). In separate groups of 10 arthritic 
mice, we administered 0.6 mg of antibody raised against murine IL-1/3. The control group received 0.6 mg of control Ig on days 32 and 35. On 
day 40, mice were killed and samples of synovium and cartilage were isolated for analysis by polymerase chain reaction (PCR). Values are the 
mean ± SD of at least 10 mice. #  = P < 0.05 versus controls, by Wilcoxon rank test. B, Synovium samples from 6 mice per group were pooled, 
and RNA was extracted. Quantitative PCR was performed as described in Materials and Methods. I = arthritic control group; II = mice treated
on day 32; III (/32m
Roughly, a 25-fold reduction (from 500 attograms to 20 ag) in the IL-1/3 mRNA level was found after treatment with rabbit anti-murine IL-1/3. 
Equal levels of DNA construct and complementary DNA (cDNA). See Figure 1 for other definitions.
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anti-IL-1 /3 on day 32 or on day 35, and mRNA was 
extracted from the synovial tissue and patellar carti­
lage on day 40. The time course of the arthritis is 
shown in Figure 7A, again proving the efficacy of 
anti-IL-1/3. Cytokine mRNA levels, as approached by 
PCR analysis are shown in Table 3. In inflamed 
synovium, a marked increase compared with normal 
synovium was found for IL-1/3 and IL-IRa, whereas 
the enhancement of TNFa and TIMP message was 
less impressive. Treatment with anti-IL-1)3 markedly 
reduced IL-1 message. This is further illustrated with 
competitive PCR and an internal standard (Figure 7B). 
Of interest, IL-IRa message was also markedly re­
duced upon anti-IL-1)8 treatment, suggesting tight 
coupling with IL-1. In contrast, the TIMP levels 
remained constant.
In the arthritic cartilage a similar trend of 
cytokine expression was observed, although values 
seemed less enhanced compared with the synovium. 
Remarkably, anti-IL-1 /3 treatment did not reduce mes­
sage expression in the chondrocytes.
DISCUSSION
TNF a is of importance at the onset of collagen- 
induced arthritis, but appears to be less dominant at 
later stages. In contrast, IL-1 seems to be a critical 
mediator both at the onset and at later stages of this 
experimental arthritis. IL-1 dependence is no longer 
apparent when the disease enters a noninflammatory 
phase, characterized by total cartilage destruction and 
the onset of ankylosis. Of interest, IL-1/3 seems to be 
the more prominent IL-1 isotype in this type of exper­
imental arthritis.
CIA is an autoimmune process directed against 
type II collagen (CII) in the articular cartilage, and the 
inflammatory process is a combination of local im­
mune complex formation at the articular cartilage 
surface and an effector T cell reaction to CII. The 
present study confirms earlier studies with neutralizing 
antibodies or with soluble TNF receptor (8,9,22), 
showing that elimination of TN Fa just after the onset 
of arthritis clearly ameliorates, but does not fully 
suppress, joint inflammation. Combination therapy 
with anti-TNFa and anti-CD4 yields more protection 
in CIA than either treatment alone (42). Anti-CD5 
therapy also causes significant suppression (43). How­
ever, one should be very careful with anti-T cell 
treatment, since at late stages of the disease, regula­
tory T cells are also involved and blocking of T cells 
may then exacerbate arthritis (44).
Table 3. Levels of cytokine mRNA in samples of inflamed tissue 
at day 40*
Cytokine
Synovium Cartilage
Control
Anti-IL-1 /3
Control
Anti-IL-1/3
Day 32 Day 35 Day 32 Day 35
IL-1/3 322 13 13 13 13 13
IL-IRa 322 25 25 47 47 47
TNFa 13 4 4 4 4 4
TIMP 7 7 7 4 4 4
* On day 40, synovium and cartilage samples were isolated as 
described in Materials and Methods. Values are the relative level of 
messenger RNA (mRNA), compared with control (nonimmunized) 
synovium or cartilage. A 24-fold decrease in mRNA levels for 
interleukin-1/3 (IL-1/3) was found after treatment with anti-IL-1/3 
antibodies. No differences were found in mRNA on day 40 when 
treatment was started either on day 32 or day 35. Values are the 
mean of 3 experiments. IL-IRa = IL-1 receptor antagonist; TNF« = 
tumor necrosis factor a; TIMP = tissue inhibitor of metalloprotei- 
nases.
The relative roles of TNF a and IL-1 in various 
stages and forms of chronic arthritis are of therapeutic 
relevance, even moreso because the present study 
clearly shows that anti-IL-1 treatment is superior to 
anti-TNFa: treatment in this particular model, and 
substantiates that inhibition of TNFa does not neces­
sarily also inhibit IL-1 production. It must be under­
scored that one should exercise caution in the overall 
interpretation of data obtained with different antibod­
ies, in view of potential differences in neutralizing 
capacity and half-lives in vivo. Moreover, antibodies 
may significantly differ in their effector functions, 
depending on the isotype. In addition to the data 
presented in this paper, we performed experiments 
with polyclonal anti-TNFa (kindly provided by S. 
Kunkel and G. Grau) and in fact confirmed the slight 
suppression after treatment of established disease (un­
published observations).
Our current data with anti-TNFa treatment are 
consistent with earlier findings in CIA (8,9,44). More­
over, our anti-TNFa was sufficiently potent to fully 
block LPS-mediated shock, whereas anti-TNFa treat­
ment was also highly suppressive in another murine 
arthritis model, streptococcal cell wall-induced arthri­
tis (Figure 4B) (45). Apparently, bacterial triggers 
provoke a more TNF-driven process. Anti-TNFa and 
anti-IL-1 treatment appeared equally effective in the 
reactivation of SCW-induced arthritis, and the best 
suppression was obtained with the combination of 
anti-IL-1 with anti-TNFa (46).
The importance of IL-1 in fully established CIA 
is now further substantiated, showing identical sup­
ANTICYTOKINE TREATMENT OF ESTABLISHED CIA 807
pression with anti-IL-1 antibodies and IL-lRa. Given 
the limited half-life of the receptor antagonist, its high 
pharmacokinetics in mice in general, and the need to 
occupy almost all IL-1 receptors to block the action of 
IL-1 (47,48), it is conceivable that profound suppres­
sion of established CIA could only be achieved with 
high levels of IL-lRa, supplied with osmotic mini­
pumps. An earlier study showed the efficacy of re­
peated, systemic dosing with IL-lRa before the onset 
of CIA (49). However, this treatment clearly sup­
pressed the anti-CII antibody levels and, apart from 
synovial inflammation, which may require different 
pharmacokinetics, probably mainly affected cellular 
processes in the lymphoid organs.
Further comparison with other arthritis models 
reveals that IL-1 is not a dominant inflammatory 
mediator in all forms of arthritis. Neither TNFa nor 
IL-1 is of key importance in the initiating inflammatory 
process of antigen-induced arthritis (26,49,50). Yet, 
elimination of IL-1 fully normalized chondrocyte pro­
teoglycan synthesis inhibition in the articular cartilage, 
proving that IL-1 is a key mediator in this character­
istic, undesired disturbance of anabolic processes in 
arthritic cartilage (26). The general validity of the latter 
role of IL-1 is now established by similar findings in 
immune complex arthritis and in T cell-driven flares of 
antigen-induced arthritis (51,52).
IL-1 blockade in CIA also profoundly reduced 
cartilage destruction, even when treatment was given 
late. Since joint inflammation was markedly sup­
pressed as well, it cannot be excluded that the protec­
tive effect on articular cartilage was indirect, through 
concomitant reduction of destructive mediators other 
than IL-1. Early anti-TNFa treatment also reduced 
cartilage destruction, consistent with its antiinflamma­
tory effect, but at later stages, no protection could be 
seen. This excludes a selective, direct role of TNFa in 
cartilage destruction. Studies with anti-IL-1 R antibod­
ies in TNF-transgenic mice provided further support 
for this (53). Although TN Fa can be destructive to 
cartilage in vitro (54), relatively high dosages are 
needed, and such a role could not be substantiated by 
intraarticular injection into the knee joints of mice and 
rabbits (25). However, in the presence of low concen­
trations of IL-1, TNFa may synergize with IL-1 (55).
To provoke the expression of slumbering CIA, 
additional TNFa appeared to be as powerful as addi­
tional IL-1 (17-20). These cytokines can induce che- 
motactic factors, and the fact that TGF/3, which is a 
powerful immunosuppressive but also a potent chemo- 
tactic factor, can also accelerate CIA expression is in
keeping with this reasoning (19,20,56,57). Recently, it 
was shown that expression can also be enhanced by 
systemic administration of LPS (30) or by local injec­
tion of Zymosan (31). Dependent on the dose, the 
latter injection caused primary expression of CIA in 
the injected joint, or spillover occurred in the draining 
limb. The inflammation in the draining site, in partic­
ular, was sensitive to anti-TNFa treatment. However, 
at both sites, anti-IL-1 treatment was superior in 
suppressing inflammation (31). Although it cannot be 
totally excluded that LPS acceleration may shift cyto­
kine balances, our present data show similar efficacy 
of anti-TNF a  and anti-IL-1 treatment in spontaneous 
(classic) CIA, as compared with LPS-accelerated CIA.
Although the severity of CIA is generally 
scored in the paws, profound inflammation is also seen 
in the knee joint. This in contrast to a rather selective 
paw involvement in classic adjuvant- and SCW- 
induced arthritis in Lewis rats (58). A great advantage 
of knee joint analysis is the higher degree of standard­
ization of histologic sections and the allowance for 
detailed analysis of message expression in defined 
samples of synovial tissue and cartilage strips.
Message expression for IL-1/3 is highly up- 
regulated in both synovium and cartilage. Anti-IL-1 /3 
treatment profoundly reduced this message in the 
synovium, but unexpectedly, the message in the car­
tilage remained high. The process in the articular 
cartilage probably is autocrine or paracrine regulated 
in that phase of the arthritis. Anti-IL-1/3 antibodies 
will not enter the cartilage, and further analysis of 
message expression and functional analysis of carti­
lage metabolism after IL-lRa treatment is warranted. 
TNFa expression seemed less enhanced compared 
with IL-1/3, but was nevertheless clearly higher than 
control values in both synovium and cartilage. TNFa 
message was also reduced in the synovium after 
anti-IL-1 /3 treatment, indicating that reduced activa­
tion of the cells in the synovium, in general, was 
achieved with such treatment.
The first clinical trials with anti-TNFa antibod­
ies in RA patients show promising symptomatic relief, 
and analysis of synovial tissue points to decreased 
expression of adhesion molecules, consistent with 
reduced cell influx and/or local cell activation (3,10— 
12). Efficacy seems to be related to the subclass of 
antibodies used. Data on protective effects against 
cartilage destruction are thus far lacking. Whether the 
process of CIA is close to that of the disease in humans 
is, of course, hard to tell, but if so, it would be 
tempting to speculate that the chronic phase of the
808 JOOSTEN ET AL
disease in humans should in fact be considered as a 
repetitive flare, given the TNF a dependence of the 
onset of CIA and bacterial flares and the relative 
insensitivity at later stages. It cannot be excluded that 
anti-IL-1 treatment would still be superior to 
anti-TNFa treatment, particularly in terms of protec­
tion against cartilage destruction. Unfortunately, good 
neutralizing humanized anti-IL-1 antibodies are not 
yet available, and the recent trials with IL-IRa have 
not been fully analyzed (3,4). Based on our observa­
tions of the need of extremely high IL-IRa dosages to 
affect cartilage proteoglycan synthesis disturbance in 
antigen-induced arthritis (26), or to suppress CIA, 
underdosing in the present clinical trials may be a 
serious concern.
Although it is difficult to extrapolate pharma­
cokinetic findings in mice to demands in humans, it is 
hoped that substantially higher doses of IL-IRa are 
being considered for upcoming trials, since the first 
results have been mediocre. Meanwhile, it is tempting 
to further invest in the development of selective IL-1- 
production inhibitors or inhibitors of IL-1-converting 
enzyme (ICE). The present data in CIA have identified 
IL-1/3 as a relevant therapeutic target in this form of 
experimental arthritis. ICE-deficient mice have re­
cently been established (59), and proper analysis of 
various forms of arthritis in these “ knock-out” mice 
seems warranted, to further identify IL-1/3 or ICE as a 
valid therapeutic target.
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